Wound Care Research
It is staggering to think that 200,000 patients in the UK suffer from chronic wounds.
REF. J Posnett et al., Nursing Times, 2008.
This is a terrible burden for the patients, and a massive financial burden on the NHS.
The total cost of treating the least severe type of chronic wound, a grade 1 pressure ulcer, starts at around £1,000. For the most severe types, the overall treatment cost can be >£20,000.
The total cost for managing wounds in the UK has been estimated at £2 – 3 billion p.a., approximately 4% of the NHS budget.
Wound Care Research at Mologic.
Mologic has a long history in developing assays for the detection of proteases, specifically those involved during the inflammatory process. In our inimitable way we later further developed these for use in lateral flow devices.
These are cheap to make, simple to use and highly suited for point of care use.
In 2008 our “ELTABA’ Technology was patented for the detection of protease activity in wound fluid.
Chemicals Produced by Neutrophil Leucocytes.
Neutrophil leukocytes have many damaging biochemical agents, which they release into the tissues where they are fighting microbes. We are focussing on one group in particular, called proteases including matrix metalloproteases MMPs and human neutrophil elastase (HNE).
Wounds are slower to heal if the levels of protease enzymes, particularly MMPs and Human Neutrophil Elastase, are high. Diagnostics capable of identifying these wounds enable the selection of the most suitable course of treatment for the patient.
When Mologic was part of the Alere group of companies, we developed a diagnostic looking at elevated protease markers.
This product was the world’s first wound diagnostic, bought to market by the diagnostic division of Systagenix (Now WOUNDCHEK Laboratories), marketed as Woundchek.
Mologic has continued to develop and improve this concept for the detection of protease levels and other markers of wound infection. A range of positive read diagnostic assays are available and already in our product development pipeline.
Combining diagnostic research with assay development has given our world-class team the edge: our expertise in assay development is growing and developing fast.
We’re attracting interest from industrial partners as well as some very exciting grant-funded activities.